Star Combo Pharma (ASX:S66) has announced the expansion of its manufacturing capabilities at its wholly-owned TGA-licensed nutraceutical manufacturing site in Sydney.
pic from:biotechdispatch
Star Combo CEO Su Zha ng said the investment underpins the company's strategy to become a leading contract manufacturer in the vitamins and dietary supplement sector.
News from:biotechdispatch
It said approximately 5 million will be invested to upgrade the existing manufacturing plant and a further 6 million for the acquisition and installation of an additional plant to establish 13 new production lines.
The project will commence in September 2020 and will be completed within two years, it said.
Contact: Sales
Phone:
Tel: +61 2 9756 6555
Email: sales@starcombo.com.au
Add: 171 - 177 Woodpark Rd, Smithfield NSW 2164